# US 2004/0082513 A1 · Enzyme-mediated modification of fibrin for tissue engineering

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082513 A1
- Document ID: US20040082513A1
- Status: Published application
- Kind: A1
- Application number: 10/650,509
- Filed: 2003-08-27
- Published: 2004-04-29
- Earliest claimed: 1997-04-03
- Assignees: California Institute of Technology
- Inventors: Jeffrey Hubbell; Jason Schense; Andreas Zisch; Heike Hall
- Web page: https://patentgrep.com/patent/US20040082513A1

## CPC

- A61L 31/046: {Fibrin; Fibrinogen}
- A61L 24/106: {Fibrin; Fibrinogen}
- A61L 27/225: {Fibrin; Fibrinogen}
- A61L 27/227: {Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24}
- C07K 14/635: Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
- C12N 5/0068: {General culture methods using substrates (for specific animal cell type C12N5/06)}
- A61F 2310/00377: Fibrin
- C07K 2319/00: Fusion polypeptide
- C12N 2533/56: Fibrin; Thrombin
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)

## Abstract

Matrices covalently bound to bidomain peptides or proteins, produced recombinantly or synthetically, contain a transglutaminase substrate domain and a bioactive factor. The bioactive factor is preferably a growth factor, such as VEGF, growth factors from the TGF-β superfamily, PDGF, human growth hormone, IGF, and ephrin. Particularly preferred growth factors are TGF-β1, BMP 2; VEGF121 and PDGF AB. The matrix material is crosslinkable, and may form a gel. These compositions are useful for tissue repair and regeneration.

## Claims

### Claim 1

A composition comprising a matrix and a recombinant bidomain protein or peptide having an amino acid sequence that comprises a transglutaminase substrate domain and a bioactive factor, wherein the protein or peptide is covalently bound to the matrix by the transglutaminase substrate domain.

### Claim 2 (depends on 1)

The composition of claim 1 wherein the matrix comprises fibrin.

### Claim 3 (depends on 2)

The composition of claim 2 wherein the transglutaminase substrate domain is a Factor XIIIa substrate domain.

### Claim 4 (depends on 3)

The composition of claim 3 wherein the Factor XIIIa substrate domain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, and SEQ ID NO: 15, and combinations and bioactive fragments thereof.

### Claim 5 (depends on 3)

The composition of claim 3 wherein the Factor XIIIa substrate domain comprises an amino acid sequence of SEQ ID NO: 15.

### Claim 6 (depends on 1)

The composition of claim 1 wherein the bioactive factor is a peptide.

### Claim 7 (depends on 1)

The composition of claim 1 wherein the bioactive factor comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, TGF-β1, BMP 2, VEGF121, PDGF AB, PTH, and combinations and bioactive fragments thereof.

### Claim 8 (depends on 1)

The composition of claim 1 wherein the bioactive factor is a polypeptide growth factor.

### Claim 9 (depends on 8)

The composition of claim 8 wherein the bioactive factor is selected from the group consisting of VEGF, a growth factor from the TGF-β superfamily, PDGF, growth hormone, IGF, and ephrin.

### Claim 10

A method of attaching a bioactive factor to a matrix, comprising
recombinantly producing a biodomain peptide or protein comprising a bioactive factor and a transglutaminase substrate domain; and
exposing the matrix to a transglutaminase to covalently couple the bidomain peptide or protein to the matrix and crosslink the matrix.

### Claim 11 (depends on 10)

The method of claim 10 wherein the matrix comprises fibrin.

### Claim 13 (depends on 10)

The method of claim 10 wherein the transglutaminase substrate domain is a Factor XlIIa substrate domain and the transglutaminase is Factor XIIIa.

### Claim 14 (depends on 13)

The method of claim 13 wherein the Factor XIIIa substrate comprises an amino acid sequence is selected from the group consisting of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, and SEQ ID NO: 15, and a combination or bioactive peptide fragment thereof.

### Claim 15 (depends on 14)

The method of claim 14 wherein the Factor XIIIa substrate comprises an amino acid sequence of SEQ ID NO: 15.

### Claim 16 (depends on 10)

The method of claim 10 wherein the bioactive factor is a polypeptide growth factor.

### Claim 17 (depends on 10)

The method of claim 10 wherein the bioactive factor is selected from the group consisting of VEGF, growth factors from the TGF-β superfamily, PDGF, growth hormone, IGF, and ephrin.

### Claim 18 (depends on 10)

The method claim 10 wherein the bioactive factor contains an acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, TGF-β1, BMP 2; VEGF121, PDGF AB, and PTH, and a combination or bioactive peptide fragment thereof.
